Elagolix
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mild Autonomous Cortisol Excess
Conditions
Mild Autonomous Cortisol Excess
Trial Timeline
Jul 6, 2021 → Jun 24, 2022
NCT ID
NCT05038878About Elagolix
Elagolix is a approved stage product being developed by AbbVie for Mild Autonomous Cortisol Excess. The current trial status is terminated. This product is registered under clinical trial identifier NCT05038878. Target conditions include Mild Autonomous Cortisol Excess.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05038878 | Approved | Terminated |
| NCT02143713 | Phase 3 | Completed |
| NCT01931670 | Phase 3 | Completed |
| NCT01760954 | Phase 3 | Completed |
| NCT01620528 | Phase 3 | Completed |
Competing Products
20 competing products in Mild Autonomous Cortisol Excess